Kidney injury as a determinant of macrophage phenotype and efficacy for treating chronic kidney disease (CKD)

肾损伤是巨噬细胞表型和治疗慢性肾病（CKD）疗效的决定因素

• 批准号: nhmrc : 457345
• 负责人: Dr Yiping Wang
• 金额: $ 36.56万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/kidney-injury-determinant-disease-ckd/98788
• 关键词: Kidney; injury; determinant; macrophage; phenotype

Chronic kidney disease (CKD) is a major cause of death and disability in the Australian population. Current treatments for CKD are non-specific and frequently ineffective. As a consequence, kidney failure progresses to the stage where patients require dialysis or tranplantation to remain alive. Every year more than 1700 Australians require kidney replacement therapy for this reason and many more die of kidney failure or its complications. Macrophage infiltration of kidneys is characteristic of CKD, and it has been assumed that macrophages cause damage. However, we have shown that certain types of macrophages can reduce kidney damage. This project will explore whether macrophage type can be switched from that causing damage to that reducing injury, with the aim of using this approach to treat CKD.

慢性肾病（CKD）是澳大利亚人口死亡和残疾的主要原因。目前 CKD 的治疗方法缺乏特异性，而且常常无效。结果，肾衰竭进展到患者需要透析或移植才能维持生命的阶段。每年有超过 1700 名澳大利亚人因此需要肾脏替代治疗，还有更多人死于肾衰竭或其并发症。巨噬细胞浸润肾脏是 CKD 的特征，人们认为巨噬细胞会造成损害。然而，我们已经证明某些类型的巨噬细胞可以减少肾脏损伤。该项目将探讨巨噬细胞类型是否可以从造成损害的类型转变为减少伤害的类型，旨在利用这种方法来治疗慢性肾病。